Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to have a significant effect in inhibiting tumor growth in recent years. However, metformin alone in cancer treatment has the disadvantages of high dose concentrations and few targeted cancer types. Increasing stu...

Full description

Bibliographic Details

Published in:	Translational Oncology
Main Authors:	Lin Zhu, Kaiqing Yang, Zhe Ren, Detao Yin, Yubing Zhou
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	Metformin Combination therapy Cancer Chemotherapy Radiotherapy Targeted therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S193652332400072X